Home›Clinical trials›Massachusetts

GLP-1 clinical trials in Massachusetts: 19 recruiting now

By John Samaras, EditorRegistry checked September 4, 2026

19 GLP-1 clinical trials are recruiting at 22 sites in 8 cities across Massachusetts. Every site below is listed with its city and, where the sponsor publishes one, the number to call.

Every study recruiting in Massachusetts

  1. PREvention of CardIovascular and DiabEtic kidNey Disease in Type 2 Diabetes

    Phase 4. Brigham and Women's Hospital plans to enroll 6,000 participants.

    A study testing whether a GLP-1 medicine, semaglutide, can help people lower blood sugar.

    Who can join. Adults 40 to 80, have type 2 diabetes.

    2 sites in Massachusetts

    NCT05390892 on ClinicalTrials.gov. See whether you qualify.

  2. GLUCOSE-MGH: Genetic Links Understood Through Challenge With Oral Semaglutide Exposure at MGH

    Phase 4. Massachusetts General Hospital plans to enroll 125 participants.

    A study testing whether a GLP-1 medicine, semaglutide, can help people with metabolic diseases lower blood sugar.

    Who can join. Adults 18 to 65, have metabolic diseases.

    1 site in Massachusetts

    • Massachusetts General Hospital, Boston. 6176435419

    NCT06003153 on ClinicalTrials.gov. See whether you qualify.

  3. A Phase 4, Prospective, Open-Label, Single Arm Study to Assess the Effectiveness of Tirzepatide After Initiation of Ixekizumab

    Phase 4. Eli Lilly and Company plans to enroll 200 participants.

    A study testing whether a GLP-1 and GIP medicine from Lilly, tirzepatide, can help people calm psoriasis.

    Who can join. Adults 18+, have psoriasis, BMI 27+.

    1 site in Massachusetts

    • Metro Boston Clinical Partners, Brighton

    NCT06857942 on ClinicalTrials.gov. See whether you qualify.

  1. LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced

    Phase 3. Boehringer Ingelheim plans to enroll 1,800 participants.

    A study testing whether a GLP-1 and glucagon medicine from Boehringer Ingelheim, survodutide, can help people reduce liver fat.

    Who can join. Adults 18+, have fatty liver disease (also called MASH or NASH) with liver scarring (fibrosis).

    1 site in Massachusetts

    NCT06632444 on ClinicalTrials.gov. See whether you qualify.

  2. A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)

    Phase 3. Eli Lilly and Company plans to enroll 125 participants.

    A study testing whether a GLP-1 medicine from Lilly, orforglipron, can help people lose weight.

    Who can join. Children and teens 6 to 17, have obesity.

    1 site in Massachusetts

    • Boston Children's Hospital, Boston

    NCT06672549 on ClinicalTrials.gov. See whether you qualify.

  3. Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative

    Phase 3. Eli Lilly and Company plans to enroll 350 participants.

    A study testing whether a GLP-1 and GIP medicine from Lilly, tirzepatide, can help people with ulcerative colitis calm gut inflammation.

    Who can join. Adults 18 to 70, have ulcerative colitis, BMI 27+.

    1 site in Massachusetts

    • Lucida Clinical Trials, New Bedford

    NCT06937086 on ClinicalTrials.gov. See whether you qualify.

  4. Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity

    Phase 3. Eli Lilly and Company plans to enroll 290 participants.

    A study testing whether a GLP-1 and GIP medicine from Lilly, tirzepatide, can help people with Crohn's disease calm gut inflammation.

    Who can join. Adults 18 to 70, have Crohn's disease, BMI 27+.

    1 site in Massachusetts

    • Lucida Clinical Trials, New Bedford

    NCT06937099 on ClinicalTrials.gov. See whether you qualify.

  5. A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Osteoarthritis (OA) of the Knee

    Phase 3. Eli Lilly and Company plans to enroll 800 participants.

    A study testing whether a GLP-1 medicine from Lilly, orforglipron, can help people ease joint pain.

    Who can join. Adults 18+, have osteoarthritis (joint pain), BMI 27+.

    1 site in Massachusetts

    NCT07153471 on ClinicalTrials.gov. See whether you qualify.

  6. A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)

    Phase 3. Eli Lilly and Company plans to enroll 4,500 participants.

    A study testing whether a GLP-1, GIP and glucagon medicine from Lilly, retatrutide, can help people reduce liver fat.

    Who can join. Adults 18+, have fatty liver disease (MASLD), BMI 25+.

    1 site in Massachusetts

    • Lucida Clinical Trials, New Bedford

    NCT07165028 on ClinicalTrials.gov. See whether you qualify.

  7. A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity

    Phase 2. Eli Lilly and Company plans to enroll 1,481 participants.

    A study testing whether an investigational medicine from Lilly, LY3305677, can help people lose weight.

    Who can join. Adults 18 to 75, have obesity, BMI 27+.

    2 sites in Massachusetts

    NCT06143956 on ClinicalTrials.gov. See whether you qualify.

The other 9 studies recruiting in Massachusetts

  1. Study of Tirzepatide for Recovery and Alcohol Use Management

    Phase 2. Brigham and Women's Hospital plans to enroll 20 participants.

    A study testing whether a GLP-1 and GIP medicine, tirzepatide, can help people with alcohol use disorder drink less.

    Who can join. Adults 18+, have alcohol use disorder, BMI 23+.

    2 sites in Massachusetts

    • Brigham and Women's Hospital, Boston
    • Brigham and Women's Faulkner Hospital, Jamaica Plain. 617-732-5752

    NCT06727331 on ClinicalTrials.gov. See whether you qualify.

  2. Effect of Tirzepatide and Bimagrumab on Body Composition, Insulin Sensitivity, and Bone in Adults With Obesity

    Phase 2. Massachusetts General Hospital plans to enroll 63 participants.

    A study testing whether a GLP-1 and GIP medicine, tirzepatide, can help people lose weight.

    Who can join. Adults 18+, have obesity, BMI 27+.

    1 site in Massachusetts

    NCT05933499 on ClinicalTrials.gov. See whether you qualify.

  3. GLP-1R Agonist Treatment for Opioid Use Disorder

    Phase 2. Milton S. Hershey Medical Center plans to enroll 200 participants.

    A study testing whether a GLP-1 medicine, semaglutide, can help people with opioid use disorder cut down on opioids.

    Who can join. Adults 18 to 75, have opioid use disorder, BMI 18+.

    1 site in Massachusetts

    • Stanley Street Treatment and Resources, Fall River. 508-324-3522

    NCT06548490 on ClinicalTrials.gov. See whether you qualify.

  4. Semaglutide for Helping Opioid Recovery

    Phase 2. Brigham and Women's Hospital plans to enroll 46 participants.

    A study testing whether a GLP-1 medicine, semaglutide, can help people with opioid use disorder cut down on opioids.

    Who can join. Adults 18+, have opioid use disorder.

    1 site in Massachusetts

    NCT06639464 on ClinicalTrials.gov. See whether you qualify.

  5. A Research Study Comparing How Well Different Doses of the Medicine NNC0662-0419 Lower Blood Sugar in People With Type 2 Diabetes

    Phase 2. Novo Nordisk A/S plans to enroll 270 participants.

    A study testing whether an investigational medicine from Novo Nordisk, NNC0662-0419, can help people with type 2 diabetes lower blood sugar.

    Who can join. Adults 18 to 75, have type 2 diabetes.

    1 site in Massachusetts

    • Brigham & Women's Hospital, Boston

    NCT07415954 on ClinicalTrials.gov. See whether you qualify.

  6. Pathways, Risk Factors, and mOleculeS to Prevent Early-onset Colorectal Tumors

    Phase 1. Massachusetts General Hospital plans to enroll 20 participants.

    A study of a GLP-1 and GIP medicine, tirzepatide, in people with colorectal adenoma.

    Who can join. Adults 18 to 50, have colorectal adenoma, BMI 27+.

    1 site in Massachusetts

    • Massachusetts General Hospital Cancer Center, Boston. 617-726-3212

    NCT07095517 on ClinicalTrials.gov. See whether you qualify.

  7. Role of Caveolin 1 (CAV-1) Deficiency in Response to Glucagon-like Peptide 1 (GLP-1) Receptor Agonist Treatment

    Brigham and Women's Hospital plans to enroll 30 participants.

    A study testing whether a GLP-1 medicine, semaglutide, can help people lose weight.

    Who can join. Adults 18+, have obesity or are overweight, BMI 27+.

    1 site in Massachusetts

    • Brigham and Women's Hospital, Boston

    NCT06069622 on ClinicalTrials.gov. See whether you qualify.

  8. Body Composition and Exercise to Prevent Muscle Loss With GLP1 Agonist Treatment

    Massachusetts General Hospital plans to enroll 100 participants.

    A study listed on ClinicalTrials.gov.

    Who can join. Adults 18+, have obesity, BMI 25+.

    1 site in Massachusetts

    NCT07226947 on ClinicalTrials.gov. See whether you qualify.

  9. Lifestyle Change Implementation Research Network at PRC at UMass Chan

    University of Massachusetts, Worcester plans to enroll 220 participants.

    A study listed on ClinicalTrials.gov.

    Who can join. Adults 18+, BMI 27+.

    1 site in Massachusetts

    • UMass Chan Medical School - Shaw Building, Worcester. 617-828-8093

    NCT07481305 on ClinicalTrials.gov. See whether you qualify.

Source: ClinicalTrials.gov, the federal registry, read September 4, 2026. Open a study's registry record before you call: it can close to new participants at any time. GLP Chart does not enroll anyone, is not paid for clinical-trial referrals and has no relationship with any sponsor or site on this page.

Screening for a study can take weeks. If you need the drug now, Strut Health is the cheapest cash route on the chart, from $149 a month. That price buys compounded semaglutide, a pharmacy-made version that is not FDA-approved and is not Wegovy, Ozempic, Zepbound or Mounjaro.

Visit Strut Health ↗

Clinical trials by state

Every state with a GLP-1 study recruiting today. 48 of them.

John Samaras, editor of GLP Chart
Written and edited by John SamarasAbout this siteContact
Why you can trust GLP Chart. Same scoring framework applied to every program. No paid placements. We never remove unfavorable information at an advertiser's request. Pricing is pulled from each program's public-facing page every Monday.